Tuesday 17 November 2026
Export ABT’s income statement to Excel — free account
Abbott Laboratories
ABTAbbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- −46.6%
- Total debt
- +140.8%
Quarter to September 2026, against a year earlier
107.41
1.11
−1.02%
Follow ABT
Alert me
Abbott Laboratories (ABT) news
The news and the share price important stories, numbered as below
Stories the last two months, newest first
More headlines
- Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump Business Wire
- Warren Buffett Says His Favorite Holding Period Is Forever. A Secretary Who Paid $180 for 3 Shares in 1935 and Never Sold Died Worth $7 Million. Here’s What Her Rule Does for $600,000 in One Stock Today 24/7 Wall St.
- Is DexCom Stock Cheaper Now That Its Multiple Has Fallen? Trefis
- Is Trending Stock Abbott Laboratories (ABT) a Buy Now? Zacks
- What Could Go Wrong At Boston Scientific From Here? Trefis
- National Advertising Division to Refer Kendal to Government Agencies and Advertising Platforms for Electing Not to Participate in Compliance Inquiry GlobeNewswire
- Tandem Diabetes Care Announces Third Quarter 2026 Financial Results Business Wire
- Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer Business Wire
- Should You Pick Boston Scientific Stock Over Its Competitors? Trefis
- Should You Buy Baxter Stock For Its Cash? Trefis
- BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 GlobeNewswire
- What Are Danaher Investors Betting On? Trefis
- Should Retail Leadership Reset Require Action From Marzetti (MZTI) Investors? Simply Wall St.
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke PR Newswire
- HSS Medical Supply Announces Distributor Agreement for Abbott's ID NOW Rapid Molecular Testing Platform PR Newswire
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System PR Newswire
- Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears? Simply Wall St.
- AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000 24/7 Wall St.